PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 6, 20260 citationsOpen Access

Expression of CLDN18.2 in Invasive Mucinous Adenocarcinomas of the Lung.

View Full Paper
KMKunio MochizukiITIppei TaharaTITOMOHIRO INOUE

Key Points

  • This research aims to investigate the expression of CLDN18.2 in invasive mucinous adenocarcinomas of the lung compared to other subtypes.
  • Examined CLDN18.2 expression in lung adenocarcinomas.
  • Compared expression levels between invasive mucinous adenocarcinomas and other major lung cancer subtypes.
  • CLDN18.2 is frequently expressed in invasive mucinous adenocarcinomas.
  • Rare expression of CLDN18.2 in other major lung cancer subtypes was observed.
  • Zolbetuximab may be a promising targeted therapy for these specific cancers.

Abstract

CLDN18.2 is frequently expressed in IMAs but rarely in other major lung cancer subtypes, suggesting that zolbetuximab may represent a promising targeted therapy for IMA.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Mochizuki et al. (2026) studied this question.

synapsesocial.com/papers/69aa6ee2531e4c4a9ff5906chttps://doi.org/10.21873/cdp.10521
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1CLDN18.2 expression identifies a gastric-type phenotype and a potential therapeutic target in pulmonary invasive mucinous adenocarcinoma2026
  2. 2Claudin 18.2 Targeting: A Pan-Cancer Perspective2026 · 1 citations
  3. 3Claudin18.2 expression and its clinicopathological feature in adenocarcinoma from various parts2024 · 9 citations
  4. 4Retrospective analysis of Claudin 18.2 expression in 64 patients with advanced gastrointestinal peritoneal disease: a potential therapeutic target for high-grade appendiceal mucinous carcinoma2026
  5. 5Claudin18.2 defines a prognostically distinct subgroup of intrahepatic cholangiocarcinoma via CD8+ T-cell exclusion2025 · 4 citations